by s2desi5_ksqtherapeutics | Jun 13, 2024 | Uncategorized
KSQ-001EX is an investigational eTIL therapy manufactured using our ExPRESS™ process in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. KSQ’s Immune CRISPRomics® platform identified SOCS1 as a top target, constraining TIL anti-tumor function,...
by s2desi5_ksqtherapeutics | Jun 14, 2024 | Uncategorized
KSQ-004EX, a dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, is also manufactured using our ExPRESS process. Using our in vivo CRISPR2TM screening approach, we identified Regnase-1 and...
by s2desi5_ksqtherapeutics | Jun 14, 2024 | Uncategorized
KSQ-4279 is a first-in-class, potent, and selective small-molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR). In July 2023, we entered into a worldwide license and collaboration agreement with Roche for the development and commercialization...
